LT
Live price temporarily unavailable.
Price history
Lantern Pharma (LTRN) is a Health Care company. Latest news and coverage below.
IPO: June 11, 2020 · $15.00 offering · NASDAQ · View IPO details →
Lantern Pharma net income history (FY2019–FY2025)
Net income
| FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Operating income | — | — | −$12.6M | −$14.4M | −$17.9M | −$22.2M | −$18.0M |
| Net income | −$2.43M | −$5.91M | −$12.4M | −$14.3M | −$16.0M | −$20.8M | −$17.1M |
| EPS (diluted) | −$1.23 | −$1.37 | −$1.13 | −$1.31 | −$1.47 | −$1.93 | −$1.57 |
| Balance sheet | |||||||
| Cash and equivalents | $1.23M | $19.2M | $51.5M | $37.2M | $21.9M | $7.51M | $4.42M |
| Total assets | $1.43M | $20.4M | $74.0M | $58.8M | $43.6M | $25.6M | $11.0M |
| Total liabilities | $489.3K | $660.8K | $2.38M | $2.80M | $2.74M | $4.38M | $4.50M |
| Shareholders' equity | $943.3K | $19.7M | $71.6M | $56.0M | $40.9M | $21.2M | $6.53M |
| Cash flow | |||||||
| Operating cash flow | −$2.13M | −$5.65M | −$10.6M | −$12.8M | −$14.3M | −$17.8M | −$15.7M |
| Capital expenditure | — | — | $15.5K | $27.8K | $18.7K | $12.6K | $1.72K |
| Free cash flow | — | — | −$10.6M | −$12.8M | −$14.4M | −$17.8M | −$15.7M |
| Share buybacks | — | — | $939.7K | $2.48M | $500.0K | — | — |
Net income
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Operating income | −$5.18M | −$5.90M | −$4.77M | −$4.65M | −$4.35M | −$4.20M | −$3.41M | −$3.51M |
| Net income | −$4.51M | −$5.88M | −$4.54M | −$4.33M | −$4.18M | −$4.07M | −$3.33M | −$7.07M |
| EPS (diluted) | −$0.42 | −$0.54 | −$0.42 | −$0.40 | −$0.39 | −$0.36 | −$0.30 | −$0.57 |
| Balance sheet | ||||||||
| Cash and equivalents | $8.10M | $7.51M | $6.38M | $6.06M | $8.39M | $4.42M | $4.92M | $6.66M |
| Total assets | $30.3M | $25.6M | $21.1M | $17.4M | $13.6M | $11.0M | $7.22M | $8.60M |
| Total liabilities | $3.70M | $4.38M | $4.32M | $4.90M | $4.04M | $4.50M | $3.78M | $11.8M |
| Shareholders' equity | $26.6M | $21.2M | $16.8M | $12.5M | $9.59M | $6.53M | $3.45M | −$3.22M |
| Cash flow | ||||||||
| Operating cash flow | −$5.58M | −$3.97M | −$4.38M | −$3.94M | −$4.57M | −$2.79M | −$3.77M | −$2.94M |
| Capital expenditure | $3.03K | $3.08K | $1.16K | $0 | $555 | $1 | — | — |
| Free cash flow | −$5.59M | −$3.97M | −$4.38M | −$3.94M | −$4.57M | −$2.79M | — | — |
From Lantern Pharma's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Lantern Pharma
- Headquarters
- Dallas, Texas From SEC filings, Oct 2026
Recent News (1)
More Health Care stocks
- ILMN Illumina
- A Agilent Technologies
- ABBV AbbVie
- ABT Abbott Laboratories
- ALGN Align Technology
- ALNY Alnylam Pharmaceuticals
- AMGN Amgen
- BAX Baxter International